(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium

@article{JimnezDaz2014SJ733AC,
  title={(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium},
  author={Mar{\'i}a Bel{\'e}n Jim{\'e}nez-D{\'i}az and Daniel H. Ebert and Yandira G. Salinas and Anupam Pradhan and Adele M. Lehane and Marie-Eve Myrand-Lapierre and Kathleen G. O’Loughlin and David M Shackleford and Mariana Justino de Almeida and Angela K. Carrillo and Julie Clark and Adelaide S M Dennis and Jonathon Diep and Xiaoyan Deng and Sandra Duffy and Aaron N. Endsley and Greg Fedewa and Wendyam Armand Guiguemde and Mar{\'i}a G. G{\'o}mez and Gloria Holbrook and Jeremy A. Horst and Charles C. Kim and Jian Liu and Marcus C. S. Lee and Amy Matheny and Mar{\'i}a Santos Mart{\'i}nez and Gregory E. Miller and Ane Rodr{\'i}guez-Alejandre and Laura X Sanz and Martina Sigal and Natalie J Spillman and Philip D. Stein and Zheng Wang and Fangyi Zhu and David Waterson and Spencer Knapp and Anang A. Shelat and Vicky M. Avery and David A. Fidock and Francisco Javier Gamo and Susan A. Charman and Jon C. Mirsalis and Hongshen Ma and Santiago Ferrer and Kiaran Kirk and I{\~n}igo Angulo-Barturen and Dennis E. Kyle and Joseph L. Derisi and David Mack Floyd and R. Kiplin Guy},
  journal={Proceedings of the National Academy of Sciences},
  year={2014},
  volume={111},
  pages={E5455 - E5462}
}
Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compounds identified by phenotypic screening. [] Key Result Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na(+) homeostasis in the parasite.

Figures from this paper

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate

The discovery and optimization of novel antimalarial compounds, the triaminopyrimidines (TAPs), which emerged from a phenotypic screen against the blood stages of Pf, highlight the potential of TAPs for single-dose treatment of Pf malaria in combination with other agents in clinical development.

SC83288 is a clinical development candidate for the treatment of severe malaria

A medicinal chemistry program starting from amicarbalide led to two compounds with optimized pharmacological and antiparasitic properties that can cure a P. falciparum infection in a humanized NOD/SCID mouse model system and support the clinical development of SC83288, as an intravenous application for the treatment of severe malaria.

Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice

Anti-malarials SJ733 and pyronaridine, though similarly efficacious in reducing overall parasitaemia in mice, differed markedly in their capacity to arrest replication and remove pRBC from circulation, suggesting similar parasite clearance curves can result for anti-malarinials with distinct capacities to inhibit, kill and clear parasites.

Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones

Although both compounds displayed similar physicochemical properties, SJ733 was more permeable but metabolically less stable than SJ311 in vitro, and was chosen as the candidate based on a more favorable dose proportionality of exposure and stronger expectation of the ability to justify a strong therapeutic index to regulators.

The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957

The antimalarial properties of DDD01034957 are detailed—a novel Antimalarial molecule which is fast-acting and potent against drug resistant strains in vitro, shows activity in vivo, and possesses a resistance mechanism linked to the membrane transporter PfABCI3.

A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin

It is shown that PfATP4G358S parasites can withstand micromolar concentrations of cipargamin and (+)-SJ733, while remaining susceptible to antimalarials that do not target Pf ATP4.

A broad analysis of resistance development in the malaria parasite

The data indicate that pre-existing resistance may not be a major hurdle for novel-target antimalarial candidates, and focusing on fast-killing compounds may result in a slower onset of clinical resistance.

Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro

An extended assay shows both drugs are individually hypnozonticidal and made more potent when partnered with chloroquine, similar to clinically relevant combinations, and shows a platform able to support screening of greater compound numbers is demonstrated.
...

References

SHOWING 1-10 OF 32 REFERENCES

Spiroindolones, a Potent Compound Class for the Treatment of Malaria

The preclinical profile for an optimized spiroindolone drug candidate, NITD609, shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.

Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite

It is argued for a complete transition to sequence-based GWAS for small, low linkage-disequilibrium genomes like that of P. falciparum, as well as many genes not previously implicated in drug-resistance roles, including genes in the ubiquitination pathway.

Chemical genetics of Plasmodium falciparum

A phenotypic forward chemical genetic approach to discover new antimalarial chemotypes and structures and biological activity of the entire library are disclosed, many of which showed potent in vitro activity against drug-resistant P. falciparum strains.

Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum

Results of these studies are consistent with the hypothesis that thymidylate synthase is the primary target of 5-fluoroorotate in malarial parasites.

Designing the next generation of medicines for malaria control and eradication

MMV presents now a suggested framework for combining the new candidates to produce the new medicines, and an outline definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are needed (target candidate profiles) is suggested.

The global pipeline of new medicines for the control and elimination of malaria

The nascent pipeline of new medicines is significantly stronger than five years ago, however, there are still risks ahead in clinical development and sustainable funding of clinical studies is vital if this early promise is going to be delivered.

Spiroindolone KAE609 for falciparum and vivax malaria.

KAE609, at dose of 30 mg daily for 3 days, cleared parasitemia rapidly in adults with uncomplicated P. vivax or P. falciparum malaria, supporting a once-daily oral dosing regimen.

Suicide for Survival - Death of Infected Erythrocytes as a Host Mechanism to Survive Malaria

Counteracting Plasmodia by inducing eryptosis is not expected to generate resistance of the pathogen, as the proteins involved in suicidal death of the host cell are not encoded by the Pathogen and thus cannot be modified by mutations of its genes.

The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases

A collection of 400 chemotypes, selected based on their drug-like properties and the others as molecular probes, are assembled, termed the Malaria Box, and can now be requested as a pharmacological test set by malaria biologists, but importantly by groups working on related parasites.